Fewer Opioids and Weaker Doses for Cancer Patients
/By Pat Anson, PNN Editor
Another study has documented how opioid guidelines over the past decade have led to fewer and weaker opioid prescriptions for cancer patients --- even though the treatment guidelines typically state they are not intended for patients suffering from cancer pain.
In findings recently published in PLOS ONE, researchers at Johns Hopkins Bloomberg School of Public Health and the University of Michigan analyzed pharmacy claims for up to 53 million privately insured U.S. adults from 2012 to 2019. During that period, opioid prescribing fell from 49.7% to 30.5% for people with chronic non-cancer pain (CNCP) and from 86% to 78.7% for people with cancer.
While the drop in prescribing appears minor for cancer patients, a closer look at the numbers shows a significant decline in high dose prescriptions and in the number of days opioids were prescribed.
In 2012, for example, the average daily dose for a cancer patient was 62.4 morphine milligram equivalents (MME). By 2019, that had fallen to 44.7 MME – a decline of over 28 percent.
The percentage of cancer patients getting over 90 MME — a ceiling recommended by the CDC for chronic non-cancer pain — fell from 26.2% to just 7.6% -- a 71 percent decrease.
The average number of days per year a cancer patient received opioids also fell, from 34.8 days to 22.3 days – a 36 percent decline.
“While clinical guidelines continue to endorse prescription opioid treatment for cancer-related pain, declines in receipt of any opioid prescription were observed for people with cancer diagnoses, though these declines were smaller in magnitude than those observed among people with CNCP diagnoses. Future research is needed to understand the clinical implications of this decline, as well as observed decreases in MME/day and days’ supply of opioid prescriptions, among cancer patients,” researchers reported.
In short, cancer patients are getting smaller and fewer doses of opioids, which researchers admit could be making their cancer pain worse. However, they stopped short of sounding the alarm over that trend and suggest it could be beneficial – by helping to reduce the risk of cancer patients overdosing.
“On the one hand, this finding may signal a cooling effect on opioid prescribing that could contribute to poorly controlled cancer pain. On the other hand, this finding may suggest reductions in high-risk opioid prescribing practices, such as high dosage prescribing, which are shown to contribute to increased risk of opioid overdose death among cancer patients,” they wrote.
Oncology experts have been warning for years that opioid prescribing guidelines are being misapplied to cancer patients, even to women with advanced breast cancer.
In 2019, a Rite Aid pharmacist refused to fill an opioid prescription for April Doyle, a California woman with Stage 4 terminal breast cancer. A tearful video she posted online went viral and the pharmacy apologized to Doyle, who later died.
That same year, the Cancer Action Network warned there has been “a significant increase in cancer patients and survivors being unable to access their opioid prescriptions.” One out of four said a pharmacy had refused to fill their prescriptions and nearly a third reported their insurer refused to pay them.
Part of the confusion about what’s appropriate for cancer pain is that the CDC’s opioid guideline says the recommendations are intended for patients “who have completed cancer treatment, are in clinical remission, and are under cancer surveillance only.” Experts say the inclusion of cancer survivors is a mistake because it is not uncommon for pain to persist long after the cancer is treated or even because of the treatment itself.
A revised draft version of the CDC guideline attempts to clear up some of the confusion by explicitly stating the recommendations are not intended for patients undergoing “cancer pain treatment” and for those in palliative or end-of-life care. The updated version of the CDC guideline is expected to be published late this year.
